CVRx (NASDAQ:CVRX) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS

CVRx (NASDAQ:CVRX) posted its quarterly earnings results on Thursday. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.52) by ($0.01), FiscalAI reports. The firm had revenue of $15.71 million for the quarter, compared to analyst estimates of $15.55 million. CVRx had a negative return on equity of 120.76% and a negative net margin of 89.14%.

Here are the key takeaways from CVRx’s conference call:

• 2026 revenue guidance was lowered to $58 million–$60 million, with third-quarter revenue expected at $13.5 million–$14.5 million, reflecting weaker anticipated second-half performance.
• Sales execution has been hampered by high turnover and slower-than-expected ramping of new territory managers, particularly in several regions with less-tenured leadership; CVRx does not expect to add sales territories for the rest of 2026.
• A major Medicare Advantage payer’s use of new prior-authorization tactics has pushed its 30-day approval rate below 30%, making physicians more hesitant to recommend Barostim for patients covered by that plan.
• Reimbursement trends outside that payer are improving, including a 60% overall Medicare Advantage 30-day approval rate, approval rates above 90% with Humana, approximately 96% payment across traditional Medicare contractors, and higher inpatient payment rates.
• CVRx reported second-quarter revenue of $15.7 million, up 16% year over year, and said the BENEFIT-HF trial is ahead of expectations for site activation and enrollment; however, the company also disclosed a Department of Justice civil investigative demand related to certain sales and marketing practices.

CVRx Trading Up 6.5%

CVRx stock traded up $0.36 during trading hours on Thursday, hitting $5.94. The stock had a trading volume of 452,909 shares, compared to its average volume of 218,213. The business’s 50 day simple moving average is $5.26 and its 200-day simple moving average is $6.52. CVRx has a one year low of $4.37 and a one year high of $11.30. The stock has a market cap of $157.65 million, a price-to-earnings ratio of -2.94 and a beta of 0.81. The company has a quick ratio of 8.89, a current ratio of 10.20 and a debt-to-equity ratio of 2.01.

Analyst Ratings Changes

A number of brokerages have weighed in on CVRX. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CVRx in a report on Monday. Wall Street Zen raised CVRx from a “sell” rating to a “hold” rating in a report on Saturday, June 27th. Finally, Canaccord Genuity Group restated a “buy” rating and set a $10.00 price objective on shares of CVRx in a research report on Tuesday, April 14th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $11.50.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Corient Private Wealth LLC acquired a new stake in CVRx during the 4th quarter worth approximately $81,000. Virtu Financial LLC acquired a new position in shares of CVRx during the fourth quarter worth $79,000. XTX Topco Ltd bought a new stake in shares of CVRx in the fourth quarter worth $90,000. Tudor Investment Corp ET AL increased its holdings in CVRx by 24.8% in the fourth quarter. Tudor Investment Corp ET AL now owns 157,260 shares of the company’s stock valued at $1,117,000 after purchasing an additional 31,200 shares during the period. Finally, Balyasny Asset Management L.P. raised its position in CVRx by 17.0% during the 4th quarter. Balyasny Asset Management L.P. now owns 814,943 shares of the company’s stock worth $5,786,000 after purchasing an additional 118,683 shares during the last quarter. Institutional investors own 75.27% of the company’s stock.

About CVRx

CVRx, Inc is a clinical-stage medical device company focused on developing a neuromodulation platform therapy for patients with cardiovascular disease. The company’s flagship product, the Barostim™ system, delivers targeted electrical stimulation to the carotid baroreceptors with the goal of modulating the body’s natural blood pressure control mechanisms. This minimally invasive, implantable therapy is designed to address unmet needs in individuals suffering from hypertension and heart failure.

The Barostim system is currently being evaluated in multiple clinical trials, including studies in resistant hypertension and advanced heart failure.